diabetes mellitus. 10 On the contrary, AMPK inhibition promotes ER stress and atherosclerosis. 11 To date, no study has examined the possible role of PPARδ in alleviating ER stress and subsequent endothelial dysfunction on AMPK activation. Therefore, we hypothesize that metformin protects against endothelial dysfunction induced by high-fat diet through restoration of AMPK/PPARδ signaling, leading to the inhibition of ER stress and superoxide generation and thus increasing NO bioavailability in the vascular wall.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PPARδ Contributes to the Beneficial Effect of Metformin on Endothelial Function in High-Fat Diet-Induced Obese Mice and in Mouse Aortae Ex Vivo
Endothelium-dependent relaxation (EDR) in response to acetylcholine was reduced in aortae from both diet-induced obese (DIO) PPARδ wild-type (WT) and knockout (KO) mice compared with control, whereas oral administration of AMPK activator metformin (100 mg/kg per day; 1 week) restored impaired EDR in DIO PPARδ WT ( Figure 1A and 1B) but not in KO mice ( Figure 1C ). In addition, incubation with AMPK inhibitor compound C (5 μmol/L; 30 minutes) inhibited metformin-induced improvement of EDR ( Figure 1B) . By contrast, phenylephrine-induced contractions in aortae with or without perivascular fats were similar in PPARδ WT and KO mice ( Figure I in the online-only Data Supplement). A positive role of ER stress in vascular dysfunction was demonstrated by impaired EDR induced by ex vivo exposure to tunicamycin (ER stress inducer; 2 μg/ mL; 16 hours). Coincubation with metformin (100 μmol/L) restored tunicamycin-attenuated EDR, which was inhibited by PPARδ antagonist GSK0660 (500 nmol/L) in aortic rings from C57BL/6J mice ( Figure 1D ). PPARδ agonist GW1516 (100 nmol/L) also reversed tunicamycin-induced impairment of EDR, which was unaffected by compound C ( Figure 1E ). One-week treatment with tauroursodeoxycholic acid (ER stress alleviator) at 100 mg/kg per day also markedly improved vasorelaxation in DIO PPARδ WT mice ( Figure IIA in the online-only Data Supplement). Acetylcholine-induced EDR was abolished by NO synthase inhibitor l-NAME ( Figure III 
Metformin Activates AMPK Which Acts on PPARδ to Alleviate ER Stress in Aortae of DIO Mice
In aortae from DIO PPARδ WT mice, AMPKα phosphorylation at Thr 172 was downregulated (Figure 2A and 2B), whereas ER stress markers such as cleaved activating transcription factor 6 (ATF6), phosphorylated eukaryotic initiation factor 2α (eIF2α) at Ser 52 , ATF3, and spliced X-box binding protein 1 were elevated compared with lean control (Figure 2A and 2C-2F). ER stress markers such as cleaved ATF6, phosphorylated eIF2α (Ser 52 ), and ATF3 were also increased in aortae from DIO PPARδ KO mice. Metformin treatment (100 mg/kg per day; 1 week) enhanced AMPKα phosphorylation in both DIO PPARδ WT and KO mice. However, metformin treatment diminished ER stress in DIO PPARδ WT but not in DIO PPARδ KO mice ( Figure 2 ).
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PPARδ Antagonist Blocks the Effect of Metformin in Alleviating ER Stress in Mouse Aortae
Coincubation with metformin (100 μmol/L) enhanced AMPKα phosphorylation at Thr 172 ( Figure 3A and 3B) and decreased tunicamycin (2 μg/mL; 16 hours)-induced upregulation of ER markers, such as cleaved ATF6, phosphorylated eIF2α (Ser 52 ), and ATF3, in aortae from C57BL/6J mice ( Figure 3A and 3C). These inhibitory effects of metformin on ER stress were diminished by GSK0660 (500 nmol/L). GW1516 (100 nmol/L) did not affect AMPK activity ( Figure 3D and 3E), whereas it reduced the expression of ER stress markers ( Figure 3D and 3F). The effect of GW1516 was unaffected by compound C (5 μmol/L).
Metformin Increases PPARδ Expression in Mouse Aortae
PPARδ was downregulated in DIO PPARδ WT mice as compared with control lean mice ( Figure 4A ). DIO PPARδ WT mice treated with metformin (100 mg/kg per day; 1 week)
showed an upregulated expression of PPARδ in aortae. The ex vivo culture of aortae with tunicamycin (2 μg/mL; 16 hours) did not affect PPARδ expression. Coincubation with metformin (100 μmol/L) increased PPARδ expression, which was inhibited by PPARδ antagonist GSK0660 (500 nmol/L; Figure 4B ). GW1516 (500 nmol/L) also increased PPARδ expression, which was unaffected by AMPK inhibitor compound C (5 μmol/L; Figure 4C ).
Genetic Knockouts or Antagonists of PPARδ Abolish Metformin-Induced Enhancement of NO Bioavailability in Mouse Aortae and Mouse Aortic Endothelial Cells
In aortae from DIO PPARδ WT mice, phosphorylation of endothelial NO synthase (eNOS) at Ser 1177 was reduced, whereas metformin treatment (100 mg/kg per day; 1 week) promoted phosphorylation; nevertheless, metformin failed to enhance eNOS phosphorylation in aortae from DIO PPARδ KO mice ( Figure 4D ). Tunicamycin (2 μg/mL; 16 hours) decreased phosphorylation of eNOS ( Figure 4E and 4F) and inhibited acetylcholine (10 μmol/L)-stimulated nitrite level ( Figure 5A ) in mouse aortae. Effects of tunicamycin were reversed by cotreatment of metformin (100 μmol/L) and GW1516 (500 nmol/L). Furthermore, tunicamycin treatment reduced the level of phosphorylated eNOS in cultured mouse aortic endothelial cells (MAECs), and this effect was prevented by coincubation with either metformin or GW1516. Again, PPARδ antagonist GSK0660 reversed the effect of metformin ( Figure V in the online-only Data Supplement). In MAECs, NO production as represented by the rise of 4-amino-5-methylamino-2',7'-difluorofluorescein fluorescence signal is triggered by the addition of Ca 2+ ionophore A23187 (1 μmol/L). Tunicamycin (2 μg/mL; 16 hours) lowered NO production, which was restored by cotreatment with metformin (100 μmol/L), whereas GSK0660 (500 nmol/L) antagonized the effect of metformin ( Figure 5B , 5C, and 5E). GW1516 (500 nmol/L) also augmented NO production in tunicamycin-treated MAECs, but its effect was not inhibited by compound C (5 μmol/L; Figure 5B , 5D, and 5E). Similar results were obtained in lysophosphatidylcholine (30 μmol/L; 16 hours)-treated MAECs ( Figure VI in the online-only Data Supplement). Treating MAECs with metformin, GW1516, GSK0660, or compound C alone showed no difference from control ( Figure VII in the online-only Data Supplement).
Metformin Acts Through PPARδ to Inhibit Superoxide Production in Mouse Aortae
The obese PPARδ WT and KO mice showed a higher level of oxidative stress in aortae compared with lean mice with the same genotype ( Figure 6A and 6B ). Chronic metformin treatment (100 mg/kg per day; 1 week) decreased the superoxide level in DIO PPARδ WT mice but was not effective in DIO PPARδ KO mice. Exposure to tunicamycin (2 μg/ mL; 16 hours) markedly increased superoxide production in aortae from C57BL/6J mice, and this superoxide elevation was reversed by cotreatment with metformin (100 μmol/L; Figure 6C ) or GW1516 (100 nmol/L; Figure 6D ). GSK0660 (500 nmol/L) blocked the reversal effect of metformin on superoxide generation ( Figure 6C ). Representative images with larger magnification are shown in Figure VIII in the online-only Data Supplement.
Discussion
The present study demonstrates a critical role of PPARδ in inhibiting ER stress and protecting endothelial function by AMPK activation in diabetic obese mice. We observed impaired vasodilatation, upregulated expressions of ER stress markers, and increased superoxide generation in aortae from DIO mice, which were reversed by chronic administration of metformin in vivo. Importantly, these protective effects of metformin were absent in DIO PPARδ KO mice.
Extensive studies have shown that metformin exerts therapeutic effects, promotes eNOS activity, and improves vascular endothelial functions in diabetes mellitus through AMPK activation. 12 The potent and selective AMPK inhibitor, compound C, abolished the vascular protective effect of metformin, supporting that metformin preserves endothelial function most likely via an AMPK-dependent mechanism. l-NAME totally inhibited EDRs in aortae, suggesting that the improved endothelial function by metformin is attributable to increased NO bioavailability.
Perivascular adipose tissue is shown to regulate vascular tone through the release of vasodilators. 13 PPARδ is widely expressed in several tissues, including adipose tissue, and hence may affect vascular function and structural remodeling. However, phenylephrine-induced contractions were similar in aortae from PPARδ WT and KO mice, although they were reduced to the same degree by the presence of perivascular fats, implying that PPARδ is unlikely to affect vascular responses through acting on perivascular adipose tissue. ER stress is mediated by 3 ER membrane-associated proteins that engage complex downstream signaling pathways, including cleavage of ATF6, activation of eIF2α/ATF3 pathway, and splicing of X-box binding protein 1. 14 All these pathways were exaggerated in obese mice and were suppressed by metformin. Our observations are in line with previous studies reporting that AMPK activation improves vascular endothelial functions 15 and mitigates ER stress 9 and reactive oxygen species (ROS) production 16 associated with diabetes mellitus. Furthermore, PPARδ is known to regulate cardiovascular function: its activation induces angiogenesis and vasculogenesis, inhibits atherosclerosis, and protects endothelial function in diabetic mice. 7 We provide novel findings that PPARδ is downstream of AMPK activation to protect endothelial function, supported by a lack of effect of metformin in obese PPARδ KO mice. This study also demonstrates that PPARδ was downregulated in DIO PPARδ WT mice as compared with control lean mice ( Figure 4A ). This result agrees with previous studies that PPARδ expression was decreased in hearts 17 and kidneys 18 of diabetic rodents. In addition, metformin increased PPARδ expression in mouse arteries. Although the detailed mechanism of how AMPK/PPARδ regulate ER stress remains incompletely understood, AMPK activation can increase the expression of 150-kDa oxygen-regulated protein (OPR150), which is an ER-associated chaperone by enhancing forkhead box O1 (FOXO1) transcriptional activity and subsequently reduces hepatic ER stress in obese mice. 19 PPARδ was found to act on FOXO signaling pathway as well. 20 PPARδ activation also protects pancreatic β-cells from ER stress through promoting fatty acid oxidation. 21 Further investigation is needed to uncover what PPARδ responsive genes are related to protein degradation and thus regulate ER stress in vasculature.
Metformin treatment did not ameliorate dyslipidemia but improved glucose metabolism ( Table I in the online-only Data  Supplement) , which might partially contribute to the beneficial effect on vascular function. Therefore, we performed ex vivo culture of mouse aortae with tunicamycin that impairs EDR, thus providing direct evidence that ER stress damages endothelial function. Metformin, as well as PPARδ agonist GW1516, reversed impairments in aortae treated with tunicamycin, where ambient glucose and lipid levels were constant. These results strongly suggest that metformin has a direct protective effect on EDR through alleviation of ER stress, independent of any effects on glucose or lipid metabolism in our mouse model of obesity.
AMPK phosphorylation has multiple targets including biosynthetic enzymes, such as acetyl-CoA carboxylase, hydroxymethylglutaryl-CoA reductase, glycogen synthase, and both eNOS and neuronal NO synthase. 22 Whereas, PPARδ agonists GW0742 and L-165041 at higher concentrations (>1 μmol/L) can directly induce vasodilatation, eNOS phosphorylation, and NO production. 23 In addition, our recent study demonstrated that another PPARδ agonist GW1516 protects endothelial function in diabetic db/db mice through an increase of eNOS activity and NO production. 7 The present data show that PPARδ mediates the effect of metformin in increasing eNOS phosphorylation in both mouse aortae and MAECs, as well as NO production, which are consistent with aforementioned observations that PPARδ improves NO bioavailability. Previous studies also implicated ER stress in oxidative stress. The accumulation of misfolded protein in ER causing ER stress leads to ROS generation through several possible mechanisms. 24 First, misfolded proteins bind protein chaperones that consume ATP, stimulating mitochondrial oxidative phosphorylation and, therefore, producing ROS as a byproduct. Second, hydrogen peroxide may be produced during disulfide bond formation in the ER. Alternatively, glutathione may be depleted during reduction of unstable or improper disulfide bonds in misfolded proteins, followed by a rise in ROS production. Finally, ER stress can lead to Ca 2+ leak from the ER and then Ca 2+ overload in the mitochondria, interrupting electron transport chain. Our data show that ER inducer, tunicamyin, elicited oxidative stress, and ER stress alleviators normalized the elevated oxidative stress, and vice versa, supporting a causal link between ER stress and oxidative stress.
Although the present study also examined the beneficial effect of metformin against ER stress stimulated by lysophosphatidylcholine, a major component of oxidized low-density lipoprotein-cholesterol in cultured MAECs, we recognize that this in vitro model cannot faithfully mimic the obese condition in mice. In future studies, attempt will be made to culture aortic endothelial cells from DIO mice and to confirm the pathological role of ER stress in vascular dysfunction related to obesity and diabetes mellitus.
The present results indicate that the ability of metformin to improve endothelial function was mediated through AMPK and PPARδ with a subsequent alleviation of ER stress and oxidative stress, as well as enhancement of eNOS activity and NO production. These findings highlight the decisive role of PPARδ downstream of AMPK activation to combat against vascular dysfunction in diabetes mellitus and obesity. 
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